Sensor based gait analysis: Diagnostic application for apomorphine titration
Objective: The goal of the present study was to quantify individual gait changes by eGaIT during the standardized titration test for subcutaneous apomorphine treatment. Background:…Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine
Objective: The objetive of our study is to assess the utility of the subtypes IgG direct Coombs test (DCT) in maintenance apomorphine treatment without risk…Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG)
Objective: Our aim was to establish whether objective measurements using the Parkinson's Kinetigraph can detect differences between patients undergoing different advanced therapy with either deep…Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia
Objective: To assess the effect of subcutaneous injection of apomorphine (APO) in patients with Parkinson's disease (PD)and morning akinesia who experience dose failures after their…Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON
Objective: Evaluate whether baseline disease severity is predictive of the effective APL-130277 dose to turn a patient with Parkinson's disease (PD) from OFF to fully…Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study
Objective: Determine the tolerance of and potential for cheek pouch buccal mucosa irritation following the administration of apomorphine film (APL-130277). Background: APL-130277 is a sublingual…APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa
Objective: Evaluate if any differences exist in the efficacy of APL-130277 doses to turn a patient with Parkinson's disease (PD) from OFF to fully ON…Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease
Objective: Determine the pharmacokinetic/pharmacodynamic effects of APL-130277 on OFF episodes in patients with Parkinson's disease (PD). Background: APL-130277 is a sublingual film being studied in…Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)
Objective: Determine the minimum MDS-UPDRS Part III improvement needed to convert a patient from the morning OFF state to a full ON with APL-130277. Background:…
- « Previous Page
- 1
- …
- 10
- 11
- 12